JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M205488200 on July 5, 2002

J. Biol. Chem., Vol. 277, Issue 37, 33799-33810, September 13, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/37/33799    most recent
M205488200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, L.
Right arrow Articles by Daugherty, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, L.
Right arrow Articles by Daugherty, B. L.

Functional Expression and Characterization of Macaque C-C Chemokine Receptor 3 (CCR3) and Generation of Potent Antagonistic Anti-macaque CCR3 Monoclonal Antibodies*

Liwen Zhang, Marco P. Soares, Yanfen Guan, Stephen Matheravidathu, Richard Wnek, Kristine E. Johnson, Anna Meisher, Susan A. IliffDagger , John S. Mudgett, Martin S. Springer, and Bruce L. Daugherty§

From the Departments of Immunology and Rheumatology and Dagger  Comparative Medicine, Merck Research Laboratories, Rahway, New Jersey 07065

Eosinophils are major effector cells implicated in a number of chronic inflammatory diseases in humans, particularly bronchial asthma and allergic rhinitis. The beta -chemokine receptor C-C chemokine receptor 3 (CCR3) provides a mechanism for the selective recruitment of eosinophils into tissue and thus has recently become an attractive biological target for therapeutic intervention. In order to develop in vivo models of inflammatory diseases, it is essential to identify and characterize the homologues of human eotaxin (C-C chemokine ligand 11) and CCR3 from other species, such as non-human primates. Accordingly, we cloned the macaque eotaxin and CCR3 genes and revealed that they were 91 and 92% identical at the amino acid level to their human homologues, respectively. Macaque CCR3 expressed in the murine pre-B L1-2 cell line bound macaque eotaxin with high affinity (Kd = 0.1 nM) and exhibited a robust eotaxin-induced Ca2+ flux and chemotaxis. Characterization of beta -chemokines on native macaque CCR3 on eosinophils was performed by means of eotaxin-induced shape change in whole blood using a novel signaling assay known as gated autofluorescence forward scatter. Additionally, mAbs were raised against macaque CCR3 using two different immunogens: a 30-amino acid synthetic peptide derived from the predicted NH2 terminus of macaque CCR3 and intact macaque CCR3-transfected cells. These anti-macaque CCR3 monoclonal antibodies exhibited potent antagonist activity in receptor binding and functional assays. The characterization of the macaque eotaxin/CCR3 axis and development of antagonistic anti-macaque CCR3 monoclonal antibodies will facilitate the development of CCR3 small molecule antagonists with the hope of ameliorating chronic inflammatory diseases in humans.

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Atherosclerosis and Endocrinology, Merck Research Laboratories, Mail Code: RY80W-107, 126 E. Lincoln Ave., Rahway, NJ 07065. Tel.: 732-594-5681; Fax: 732-594-7926; E-mail: bruce_daugherty@merck.com.

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
T. Morokata, K. Suzuki, Y. Masunaga, K. Taguchi, K. Morihira, I. Sato, M. Fujii, S. Takizawa, Y. Torii, N. Yamamoto, et al.
A Novel, Selective, and Orally Available Antagonist for CC Chemokine Receptor 3
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 244 - 250.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Gupta, S. Schulz-Maronde, C. Kutzleb, R. Richter, W.-G. Forssmann, A. Kapp, U. Forssmann, and J. Elsner
Cloning, expression, and functional characterization of cynomolgus monkey (Macaca fascicularis) CC chemokine receptor 1
J. Leukoc. Biol., November 1, 2005; 78(5): 1175 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
D. L. Chou, B. L. Daugherty, E. K. McKenna, W. M. Hsu, N. K. Tyler, C. G. Plopper, D. M. Hyde, E. S. Schelegle, L. J. Gershwin, and L. A. Miller
Chronic Aeroallergen during Infancy Enhances Eotaxin-3 Expression in Airway Epithelium and Nerves
Am. J. Respir. Cell Mol. Biol., July 1, 2005; 33(1): 1 - 8.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
M. F. Goldberg
The Skin Is Not the Predominant Problem in Incontinentia Pigmenti
Arch Dermatol, June 1, 2004; 140(6): 748 - 750.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.